vs

Side-by-side financial comparison of Surrozen, Inc. (SRZN) and TRANSACT TECHNOLOGIES INC (TACT). Click either name above to swap in a different company.

TRANSACT TECHNOLOGIES INC is the larger business by last-quarter revenue ($11.5M vs $10.0M, roughly 1.1× Surrozen, Inc.).

Surrozen, Inc. is a clinical-stage biotechnology company dedicated to developing targeted regenerative therapies based on the Wnt signaling pathway. Its product pipeline covers unmet medical needs in ophthalmology, gastrointestinal diseases and other severe chronic conditions, serving global patient groups and collaborating with industry partners to advance innovative treatment accessibility.

Roper Technologies, Inc. is a holding company that owns companies in the technology sector.

SRZN vs TACT — Head-to-Head

Bigger by revenue
TACT
TACT
1.1× larger
TACT
$11.5M
$10.0M
SRZN

Income Statement — Q3 FY2024 vs Q4 FY2025

Metric
SRZN
SRZN
TACT
TACT
Revenue
$10.0M
$11.5M
Net Profit
$-1.4M
Gross Margin
47.6%
Operating Margin
12.3%
-10.1%
Net Margin
-14.3%
Revenue YoY
11.9%
Net Profit YoY
86.3%
EPS (diluted)
$-0.44
$-0.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
SRZN
SRZN
TACT
TACT
Q4 25
$11.5M
Q3 25
$13.2M
Q2 25
$13.8M
Q1 25
$13.1M
Q4 24
$10.2M
Q3 24
$10.0M
$10.9M
Q2 24
$0
$11.6M
Q1 24
$0
$10.7M
Net Profit
SRZN
SRZN
TACT
TACT
Q4 25
Q3 25
$15.0K
Q2 25
$-143.0K
Q1 25
$19.0K
Q4 24
Q3 24
$-1.4M
$-551.0K
Q2 24
$-25.3M
$-319.0K
Q1 24
$-8.8M
$-1.0M
Gross Margin
SRZN
SRZN
TACT
TACT
Q4 25
47.6%
Q3 25
49.8%
Q2 25
48.2%
Q1 25
48.7%
Q4 24
44.2%
Q3 24
48.1%
Q2 24
52.7%
Q1 24
52.6%
Operating Margin
SRZN
SRZN
TACT
TACT
Q4 25
-10.1%
Q3 25
0.1%
Q2 25
-1.9%
Q1 25
-0.1%
Q4 24
-10.3%
Q3 24
12.3%
-7.7%
Q2 24
-3.8%
Q1 24
-12.2%
Net Margin
SRZN
SRZN
TACT
TACT
Q4 25
Q3 25
0.1%
Q2 25
-1.0%
Q1 25
0.1%
Q4 24
Q3 24
-14.3%
-5.1%
Q2 24
-2.8%
Q1 24
-9.7%
EPS (diluted)
SRZN
SRZN
TACT
TACT
Q4 25
$-0.11
Q3 25
$0.00
Q2 25
$-0.01
Q1 25
$0.00
Q4 24
$-0.80
Q3 24
$-0.44
$-0.06
Q2 24
$-7.99
$-0.03
Q1 24
$-4.24
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
SRZN
SRZN
TACT
TACT
Cash + ST InvestmentsLiquidity on hand
$31.0M
$20.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$5.7M
$31.1M
Total Assets
$48.0M
$44.8M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
SRZN
SRZN
TACT
TACT
Q4 25
$20.4M
Q3 25
$20.0M
Q2 25
$17.7M
Q1 25
$14.2M
Q4 24
$14.4M
Q3 24
$31.0M
$11.3M
Q2 24
$37.8M
$11.1M
Q1 24
$27.3M
$10.6M
Stockholders' Equity
SRZN
SRZN
TACT
TACT
Q4 25
$31.1M
Q3 25
$31.8M
Q2 25
$31.3M
Q1 25
$30.9M
Q4 24
$30.6M
Q3 24
$5.7M
$38.4M
Q2 24
$6.1M
$38.5M
Q1 24
$30.1M
$38.6M
Total Assets
SRZN
SRZN
TACT
TACT
Q4 25
$44.8M
Q3 25
$45.0M
Q2 25
$44.5M
Q1 25
$44.2M
Q4 24
$44.0M
Q3 24
$48.0M
$50.5M
Q2 24
$45.1M
$50.4M
Q1 24
$36.7M
$51.9M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
SRZN
SRZN
TACT
TACT
Operating Cash FlowLast quarter
$-6.8M
$609.0K
Free Cash FlowOCF − Capex
$589.0K
FCF MarginFCF / Revenue
5.1%
Capex IntensityCapex / Revenue
0.0%
0.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$7.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
SRZN
SRZN
TACT
TACT
Q4 25
$609.0K
Q3 25
$3.6M
Q2 25
$3.6M
Q1 25
$-161.0K
Q4 24
$2.4M
Q3 24
$-6.8M
$327.0K
Q2 24
$-5.6M
$636.0K
Q1 24
$-8.7M
$-1.5M
Free Cash Flow
SRZN
SRZN
TACT
TACT
Q4 25
$589.0K
Q3 25
$3.6M
Q2 25
$3.6M
Q1 25
$-171.0K
Q4 24
$2.4M
Q3 24
$259.0K
Q2 24
$499.0K
Q1 24
$-8.8M
$-1.6M
FCF Margin
SRZN
SRZN
TACT
TACT
Q4 25
5.1%
Q3 25
27.1%
Q2 25
25.9%
Q1 25
-1.3%
Q4 24
23.2%
Q3 24
2.4%
Q2 24
4.3%
Q1 24
-14.9%
Capex Intensity
SRZN
SRZN
TACT
TACT
Q4 25
0.2%
Q3 25
0.5%
Q2 25
0.1%
Q1 25
0.1%
Q4 24
0.1%
Q3 24
0.0%
0.6%
Q2 24
1.2%
Q1 24
1.0%
Cash Conversion
SRZN
SRZN
TACT
TACT
Q4 25
Q3 25
242.00×
Q2 25
Q1 25
-8.47×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons